Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type
about
Is urotensin-II the new endothelin?Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1EndothelinThe role of the intestinal microcirculation in necrotizing enterocolitisEvidence that ET-1, but not ET-3 and S6b, ET(A)-receptor mediated contractions in isolated rat mesenteric arteries are modulated by co-activation of ET(B) receptorsNitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system[(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in manVasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitroThromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartanETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitroCharacterization of the binding of endothelin ETB selective ligands in human and rat heartCharacterization of [125I]-PD164333, an ETA selective non-peptide radiolabelled antagonist, in normal and diseased human tissuesRole of ERK/MAPK in endothelin receptor signaling in human aortic smooth muscle cells.Hypoxaemia and release of endothelin-1Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma.Antihypertensive agents in hemodialysis patients: a current perspective.Endothelin receptor subtypes and their functional relevance in human small coronary arteriesEndothelin receptor expression and pharmacology in human saphenous vein graft.Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide.Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells.Effects of the ETA/ETB receptor antagonist, bosentan on endothelin-1-induced myocardial ischaemia and oedema in the rat.Endothelin receptors in human coronary artery and aortaEffects of calcium antagonists on endothelin-1-induced myocardial ischaemia and oedema in the ratFailure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experimentsCardiopulmonary indications for endothelin receptor antagonists: review of recent efficacy trials.Endothelin-receptor antagonists in arterial hypertension: further indications?RGDN peptide interaction with endothelial alpha5beta1 integrin causes sustained endothelin-dependent vasoconstriction of rat skeletal muscle arterioles.Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.An update on the use of ambrisentan in pulmonary arterial hypertension.Endothelin antagonism and its role in the treatment of hypertension.Lung Circulation.Inhibitors of endothelin.Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation.Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat.Effect of selective blockade of endothelin ETB receptors on the liver dysfunction and injury caused by endotoxaemia in the ratCharacterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart.Localization and function of ET-1 and ET receptors in small arteries post-myocardial infarction: upregulation of smooth muscle ET(B) receptors that modulate contractionPlasticity of contractile endothelin-B receptors in human arteries after organ culture.The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044.Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm.
P2860
Q24672927-B2282E0A-5933-4714-8AC6-6E63CE847FCFQ24674639-AD892B11-FA60-465A-B066-F3156F7F9E07Q26767156-769C4D59-7CC4-449B-A6B1-E53A64B95B36Q27691434-ACF8C85C-6013-4B25-8D8B-480189962382Q28343934-15807FCF-95B9-4843-8537-F431DB765485Q28345869-3C92AE84-EA10-4CD5-A560-070828B7203DQ28360176-10F7E433-A2D9-4B43-86DF-E5F6C6258761Q28363807-CA91BCAA-05BD-4DEE-A4A2-47F7BE513422Q28365334-F8F68B9D-DD7E-48F2-9A16-7F52C1BA4C05Q28367973-F2729EBB-D90C-4124-9350-6CF173E5103CQ28379280-73848E6A-38F3-4E5A-901C-DBC049106C48Q28379363-6B38B0F4-5C7A-4D33-B30E-C57F7D677F07Q33477974-0ABBA3E7-35B6-4710-8D59-A97308EB5D2BQ33605325-02EC32A9-304B-410F-A55A-BF7550B21A24Q33923465-6F6DC2AE-37BC-4AED-A6C7-E96287323E9EQ34700870-47E0D9CF-D3AF-48CC-A4D4-7C53E345B14EQ35027611-A1A2A4A8-B285-41D3-AC10-2F31BACEE7C5Q35028439-9B6830D4-7A3F-4BD3-B329-3276245FB1D6Q35595423-3D166100-60DD-49CA-99F8-73350A566133Q35872946-26FD7D87-FD7E-4F81-94C0-A55EF7C0EE81Q35873024-16BD5E46-7B9A-47B8-A799-7CCCFBB84866Q35873397-2CF43DB4-262D-4A3A-88B5-B5EEF67DB212Q35873579-D0F83529-3DD8-4120-9BC7-FC4478583230Q35873739-A7F3A6FE-C014-4180-94F9-36AD0E9D8750Q36179755-51317184-AA05-416F-92F8-E6C776B93571Q36760532-223B935E-9728-4DCE-9352-0C96599979A0Q37372789-C12DB4AF-FA0E-4ABF-9DC6-C14085B3579BQ37972127-82AAA563-2433-40DC-A9CF-8E3BA61C9213Q38039046-70B59C0B-BBE4-401C-8457-D1BF84CD9842Q38126405-0E964CA7-23C2-476C-855B-47D861DDD82FQ38804579-B7AF1AB0-AFB2-48A0-A22F-80BCFB6D6D63Q41287170-4CF7822D-B506-4D3C-83AF-DC66D8C1AE94Q41604430-9F70110B-33E4-4754-B071-4F5171D4474DQ41790851-C791972F-1B48-42B9-8FBD-83B3ED63F08AQ41841070-C182CEFD-68A4-44DD-AFCA-3AC1FF707ABDQ41972819-D965BC3E-CB9D-46F7-84AC-6B41DD88D1F3Q42128081-EEAE9EA9-A4F3-4F4E-8B32-7269FE0CBD69Q42204748-00372F79-AFE3-4E69-9A44-85E4263DA01BQ42580908-5491930E-19D0-4EE6-ABDD-93B41064E369Q42707451-11256D71-D2CB-47C6-B933-76DDADC412DD
P2860
Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type
description
1995 nî lūn-bûn
@nan
1995 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մարտին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
name
Endothelin ETA and ETB mRNA an ...... : majority of the ETA sub-type
@ast
Endothelin ETA and ETB mRNA an ...... : majority of the ETA sub-type
@en
Endothelin ETA and ETB mRNA an ...... : majority of the ETA sub-type
@nl
type
label
Endothelin ETA and ETB mRNA an ...... : majority of the ETA sub-type
@ast
Endothelin ETA and ETB mRNA an ...... : majority of the ETA sub-type
@en
Endothelin ETA and ETB mRNA an ...... : majority of the ETA sub-type
@nl
prefLabel
Endothelin ETA and ETB mRNA an ...... : majority of the ETA sub-type
@ast
Endothelin ETA and ETB mRNA an ...... : majority of the ETA sub-type
@en
Endothelin ETA and ETB mRNA an ...... : majority of the ETA sub-type
@nl
P2093
P2860
P1476
Endothelin ETA and ETB mRNA an ...... : majority of the ETA sub-type
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.1995.TB13322.X
P407
P577
1995-03-01T00:00:00Z